MLTX vs IMTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MLTX Captures Institutional Edge (2โ1 Pillars ยท 3โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) driven by superior Momentum & Technical, Options & Structure while IMTX counters with relative strength in Growth & Margin. Fundamentally, MLTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus IMTX at N/M Forward P/E and -577.1% operating margin (+33.5% YoY). In options structure, MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against IMTX sits in BREAKDOWN (84th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MLTX | IMTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.1B | $992.8M | Larger Scale | MLTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +33.5% | Higher Growth | IMTX |
| Operating Margin (TTM) Profitability | 0.0% | -577.1% | Higher Margin | MLTX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -81.5% | -54.3% | Higher ROE | IMTX |
| 52-Week Range Position Momentum | 17% ($9โ$23) | 2% ($6โ$12) | Stronger Trend | MLTX |
| Beta / 30D Volatility Risk Regime | 1.61ฮฒ ยท 90% Vol | 1.42ฮฒ ยท 54% Vol | Lower Realized Risk | IMTX |
| Unified Institutional Score Composite Signal | 38.3 / 100 (SELL) | 49.7 / 100 (HOLD) | Higher Composite | IMTX |